German drug maker Boehringer Ingelheim has won approval from the Indian drug regulator to market its top-selling type-2 diabetes medication Jardiance (empagliflozin) in India, for additional indication to reduce the risk of heart failure in adults.
Copyright © 2024 | WordPress Theme by MH Themes